> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Revises Guidance on Compounding Ibuprofen
- URL: https://www.fdaweb.com/fda-revises-guidance-on-compounding-ibuprofen/
- Published: 2023-02-09T12:00:00.000Z
- Updated: 2026-09-14T18:15:19.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5153746

FDA has revised its emergency guidance on compounding certain ibuprofen oral suspension products to address ongoing product shortages. Last month, FDA has issued an [immediately-in-effect guidance on compounding certain ibuprofen products](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compounding-certain-ibuprofen-oral-suspension-products-under-section-503b-federal-food-drug-and?ref=fdaweb.com), which describes regulatory and enforcement priorities regarding the compounding of certain ibuprofen oral suspension products in outsourcing facilities for use in hospitals and health systems. An increase in demand has been attributed to recent surges in Covid-19, respiratory syncytial virus and influenza, any of which can cause fever in young children.

The [revision](https://www.fda.gov/drugs/drug-safety-and-availability/fda-issues-guidance-help-increase-supply-ibuprofen-oral-suspension-products-hospitals-and-health?utm%5Fmedium=email&utm%5Fsource=govdelivery) “addresses outsourcing facilities providing certain ibuprofen oral suspension products to state-licensed pharmacies (including those within hospitals and health systems) and applicable federal facilities to dispense to patients for home use, following receipt of a valid, patient-specific prescription from a health care provider,” the agency says.